[Nature sub-issue] Combining two clinical cancer drugs, "two-pronged" treatment of specific colorectal cancer

This article was originally written by Translational Medicine.
Please indicate the source.
Author: Ashley Introduction: A recent study of colon cancer with specific partial mutations of the PIK3CA gene found that the combination drug Apelisib and Tazemostat was effective in targeting two signaling pathways involved in these mutations
.

The data showed that cancer tumors continued to grow in the mouse model when treated with just one drug, but shrank when treated with the dual-drug combination
.

Based on their findings, clinical trials using the drug combination to treat this type of colorectal cancer are expected to begin in human patients later this year
.

A new study, "Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer," recently published in Nature Communications, shows that researchers at Case Western Reserve University School of Medicine found that combining two cancer drugs can effectively treat one.
a specific type of colorectal cancer
.

https:// Their study focused on a type of colon cancer involving mutations in specific parts of the PIK3CA gene, which is known to account for approximately 25,000 colorectal cancer patients annually in the United States— - About 15% of colorectal cancers
.

The Case Western Reserve-led team found evidence that the combination drugs Apelisib and Tazemostat are effective in targeting two signaling pathways involved in these mutations
.

Based on their findings, clinical trials using the drug combination to treat this type of colorectal cancer are expected to begin in human patients later this year
.

"The efficacy of drug combinations needs to be tested in cancer patients
.

" We are actively pursuing a Phase 1 clinical trial in patients whose tumors have this genetic mutation, led by oncologist Dr.
David Bajor
.
" "Tazemostat is an FDA-approved clinical drug for a class of blood cancers, and the drug Apelisib is FDA-approved for some breast cancers .
Colorectal cancer is the second leading cause of cancer-related death, according to the National Cancer Institute, in 2022.
As many as 151,000 new cases of colorectal cancer will be diagnosed in 2019.
Understanding PIK3CA Tumor Mutation Cancer development is driven by oncogenes, which act as "gas pedals" to accelerate growth when mutated .
Instead, tumors The suppressor gene acts as a brake that slows cancer cell growth .
Some types of hard-to-treat colorectal cancer tumors contain mutations in the oncogene PIK3CA, which the researchers say is involved in about 30 percent of colorectal cancers and 20 percent of all human cancers Mutations in PIK3CA are found in as many as 40 tumor types and are estimated to be present in 4 million patients worldwide each year .
" There is currently no targeted therapy for PIK3CA-mutated colorectal cancer, and our study may lead to new therapeutic options .
" "The scientists wanted to target PIK3CA mutations that occur in the helical region, which, according to Wang, is a hotspot for mutations .
The team hypothesized that PIK3CA mutations in the helical region and its two related pathways could hold the solution .























"PIK3CA cancer cells mutate in two distinct pathways, and both must be chemically inhibited, which is where the two-drug combination therapy comes into play,
"
Wang said
.

By studying colorectal tumor cells in research models, the scientists were able to determine that a two-pronged drug treatment option involving Tazemostat and Apelisib would be most effective
.

Reference: https://medicalxpress.
com/news/2022-05-combining-clinical-cancer-drugs-specific.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.

For health guidance, please go to a regular hospital for treatment
.

Recommendation·Activity Click on the text or scan the QR code to view the details.
May 6th, 14:00-15:00 Online Seminar on the Application of Ultra-Multiplex Digital PCR Technology to the Detection of Tumor Minimal Residual (MRD) Scanning Appointment Live May 11th 15:00-17:00 Online Seminar on Epiomics and Disease Regulation Scanning Appointment Live May 18th 19:00-21:30 Online "Medicine Precision" Issue 5: Focus on Drug Targets - MET Targeting Live broadcast of drug development and progress scanning appointment